Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saredutant in Generalized Anxiety Disorder
NCT00417118Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of saredutant in generalized anxiety disorder (GAD) (3 arms), sponsored by Sanofi. Primary endpoint: Hamilton Anxiety Rating Scale at Day 56. Started Dec 2006; status: completed.
02
Drugs
saredutant
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00417118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417118.